Table I.
Median age (years) | 50 (range:26–84) |
Postmenopausal | 54 (46%) |
Median tumor size (cm) | 2.2 (range:1–6) |
Lymph node-positive | 93 (79%) |
ER/PR-positive | 94 (80%) |
Adjuvant hormonal treatment | 88 (94%) |
No adjuvant hormonal treatment | 2 (2%) |
Adjuvant hormonal treatment unknown | 4 (4%) |
Her2-positive | 26 (22%) |
Recurrence | 17 (14%) |
Adjuvant chemotherapy | |
Doxorubicin and cyclophosphamide | 90 (76%) |
Additional taxane therapy | 69 (58%) |